Skip to main content

Table 3 Secondary data analysis and DNA micro arrays. Secondary data analysis was performed on data published by Dhanasekaran et al. [19] to identify adhesion molecules the expression that are altered during prostate cancer progression. Comparisons were made between normal (norm) tissue/benign prostate hyperplasia (BPH) and cancer (CaP) and metastasis (Met). The normalized mean and standard deviation values were evaluated for significance with Instat 4.0 (GraphPAD software) using one-way analysis of variance (ANOVA) are presented, with the level of significance set at p < 0.05 (*). To determine which of the genes are responsive to CXCL12, RNA was analyzed from CXCL12 treated LNCaP and LNCaP C4-2B cells (200 ng/ml, 2 hours) were compared against non-treated cells by DNA micro array using the Human genome U133 gene chips (Affymetrix Corp. Santa Clara, CA). Later, fold change values were determined using DNA-Chip (dChip version 1.1) [26].

From: The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis

   BPH/Norm Vs CaP BPH/Norm Vs Met CaP Vs Met Fold Change: LNCAP Fold Change: LNCaP C4-2B
Gene Gene Symbol Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D.
activated leucocyte cell adhesion molecule ALCAM 2.34 0.86 1.19 0.76 1.97 0.84 1.04 0.68 1.19 1.47
cadherin 11, type 2, OB-cadherin (osteoblast) CDH11 2.76 0.20* 1.01 0.27* 2.80 0.27* -1.09 1.17 -1.38 0.65
cadherin 3, type 1, P-cadherin (placental) CDH3 3.07 0.27 1.11 0.35 2.87 0.38 -1.19 0.57 -1.06 0.76
cadherin 5, type 2, VE-cadherin (vascular epithelium) CDH5 1.00 0.37 3.50 1.01 1.00 0.82 -1.03 0.95 -1.12 1.23
CD 3G antigen, gamma polypeptide (TiT3 complex) CD3G 2.11 0.22 1.12 0.21 1.90 0.27 -1.07 0.68 1.01 0.91
CD 8 antigen, alpha polypeptide (p32) CD8A 3.24 0.24 1.05 0.24* 3.15 0.25 -1.38 0.60 1.26 0.93
CD 34 antigen CD34 3.56 0.15 1.20 0.16 2.94 0.16 -1.65 0.85 1.21 0.62
CD 36 antigen (collagen type I/thrombospondin receptor) CD36 1.96 0.21 1.32 0.33* 1.47 0.37* 1.19 1.07 1.02 0.47
CD 53 antigen CD53 2.17 0.43* 0.56 0.45 3.84 0.24 -1.05 0.85 -1.02 1.06
CD 68 antigen CD68 3.31 0.28 1.04 0.25 3.14 0.23 -1.43 0.55 1.02 0.31
CD 79A antigen (immunoglobulin-associated alpha) CD79A 3.83 0.25 1.27 0.26* 2.98 0.23* 1.19 0.54 -1.25 0.64
CD 151 antigen CD151 2.10 0.18 0.88 0.16 2.36 0.17* 1.10 0.92 -1.14 0.81
CD 164 antigen, sialomucin CD164 2.42 0.50 0.68 0.52* 3.58 0.28* 1.32 0.65* 1.95 0.49*
endothelial cell-specific molecule 1 EMAP1 3.01 0.24 1.18 0.30 2.61 0.34* -3.61 2.14 -2.23 0.36
integrin, alpha 1 ITGA1 1.72 0.60* 0.43 0.70* 4.09 0.34* -1.05 1.20 -1.20 0.62
integrin, alpha 2 (CD49B, subunit of VLA-2 receptor) ITGA2 2.06 0.52* 0.53 0.56* 3.93 0.26 1.10 1.84 -1.11 0.97
integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) ITGB3 2.46 0.15 1.08 0.15 2.37 0.12 -1.07 1.00 1.06 0.37*
integrin, beta 4 ITGB4 3.22 0.24* 0.62 0.27 4.53 0.21 -1.04 0.73 -1.34 0.59
integrin, beta 5 ITGB5 2.60 0.20 1.18 0.22 2.19 0.19 1.09 1.11 1.01 1.11
integrin, alpha 8 ITGA8 2.09 0.41 0.48 0.32 4.12 0.23 1.14 0.51 1.01 0.87
integrin, alpha V (vitronectin receptor, CD51) ITGAV 2.10 1.53 0.35 1.40 5.45 0.16* 1.19 0.44* 1.37 0.29
integrin, alpha L (antigen CD11A) ITGAL 3.48 0.15 0.90 0.16 3.82 0.91 -1.17 0.68 1.24 0.53
protocadherin 1 (cadherin-like 1) PCDH1 4.36 0.24 0.94 0.28 4.32 0.28 -1.48 0.37 1.17 0.46
platelet/endothelial cell adhesion molecule (CD31 antigen) PECAM1 3.15 0.25 0.96 0.26 3.26 0.25 1.08 0.83 -1.02 0.67
selectin E (endothelial adhesion molecule 1) SELE 1.60 1.22 0.33 1.27 4.86 0.30 1.03 0.83 1.10 0.67
syndecan 2 SDC2 2.16 0.34* 0.59 0.37* 3.66 0.17* -1.12 1.40 1.01 0.76
syndecan 4 SDC4 3.34 0.31* 1.16 0.30 2.95 0.33 1.01 1.21 1.13 0.84
vascular cell adhesion molecule 1 VCAM1 2.34 0.20* 0.91 0.24 2.62 0.23 1.24 1.43 -1.02 0.83